Protocols

Biotech makes a $303M run on Wall Street; Billionaire Thiel backs a startup round for antibiotic developer

⇨  It’s been another big week on the biotech IPO front. Deciphera $DCPH went public, raising $128 million for its solid tumor work, sticking to the top of the range at $17 a share. The UK’s Nightstar Therapeutics $NITE team — a gene therapy company — hit the middle of the range, raising $75 million at $14 a share. And NuCana, another UK biotech which jumped to Nasdaq, scored a cool $100 million from its IPO. NuCana says it is working on next-gen chemotherapies. Add it all up and you have a picture of a thriving biotech market, which is certain to attract more S-1s as the industry enjoys another upbeat run of new offerings.

⇨ Silicon Valley billionaire Peter Thiel has a new upstart biotech to add to his portfolio. Thiel was credited as one of the lead investors in a $5.5 million Series A for Peptilogics, a new antibiotics company founded by Jonathan Steckbeck to tackle multidrug-resistant bacterial infections. Stefan Roever, BlueTree Ventures and others also jumped in.

⇨ Rumor has it that AAA — France’s Advanced Accelerator Applications — is on the auction block, with Novartis giving it a once over. If so, they just got a boost with the European OK for their drug Lutathera for gastroenteropancreatic neuroendocrine tumors.

⇨ IPOs aren’t the only offerings to do well these days. Follow-ons keep pumping money into the business, as Intra-Cellular Therapies $ITCI proved with a new $140 million raise.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->